Long-acting injectable ART offers better QoL for PLHIV
13 May 2024
byDr. Chia-Jui Yang, Dr. Beng Eu
The focus of HIV care has shifted beyond viral suppression towards addressing the holistic needs of people living with HIV (PLHIV) as advances in HIV treatment have considerably extended the lifespan of these patients. At a scientific meeting organized by the Hong Kong Society for HIV Medicine, Dr Chia-Jui Yang of the Department of Internal Medicine, Far Eastern Memorial Hospital (FEMH), Taipei, Taiwan, discussed the importance of implementing patient-reported outcome measures (PROMs) to improve HIV care. Dr Beng Eu of the Prahran Market Clinic, Melbourne, Australia, highlighted a long-acting (LA) antiretroviral therapy (ART) regimen comprising 2-monthly injectable cabotegravir (Vocabria, GlaxoSmithKline) plus rilpivirine as a viable alternative to oral HIV treatment for potentially improving the overall quality of life (QoL) of PLHIV.